Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2007, p. 2123-2129, Vol. 51, No. 6
0066-4804/07/$08.00+0 doi:10.1128/AAC.01454-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Instituto de Parasitología y Biomedicina López-Neyra, Parque Tecnológico de Ciencias de la Salud, Avenida del Conocimiento, s/n, 18100-Armilla, Granada, Spain,1 Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardif CF10 3XF, United Kingdom,2 Swiss Tropical Institute, Socinstrasse 57, P.O. Box, CH-4002 Basel, Switzerland,3 Laboratorio de Química Biológica, Centro de Bioquímica y Biofísica, Instituto Venezolano de Investigaciones Científicas, Altos de Pipe, Km. 11, Carretera Panamericana, Caracas 1020, Venezuela4
Received 20 November 2006/ Returned for modification 9 January 2007/ Accepted 13 March 2007
The biosynthesis of sterols is a major route for the development of antitrypanosomals. Squalene synthase (SQS) catalyzes the first step committed to the biosynthesis of sterols within the isoprenoid pathway, and several inhibitors of the enzyme have selective antitrypanosomal activity both in vivo and in vitro. The enzyme from Trypanosoma cruzi is a 404-amino-acid protein with a clearly identifiable membrane-spanning region. In an effort to generate soluble recombinant enzyme, we have expressed in Escherichia coli several truncated versions of T. cruzi SQS with a His tag attached to the amino terminus. Deletions of both the amino- and carboxyl-terminal regions generated active and soluble forms of the enzyme. The highest levels of soluble protein were achieved when 24 and 36 amino acids were eliminated from the amino and carboxyl regions, respectively, yielding a protein of 41.67 kDa. The Michaelis-Menten constants of the purified enzyme for farnesyl diphosphate and NAD (NADPH) were 5.25 and 23.34 µM, respectively, whereas the Vmax was 1,428.56 nmol min1mg1. Several quinuclidine derivatives with antiprotozoal activity in vitro were found to be selective inhibitors of recombinant T. cruzi SQS in comparative assays with the human enzyme, with 50% inhibitory concentration values in the nanomolar range. These data suggest that selective inhibition of T. cruzi SQS may be an efficient strategy for the development of new antitrypanosomal agents.
Published ahead of print on 19 March 2007.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»